PARP Inhibitors for Cancer Therapy
Sign Up to like & getrecommendations! Published in 2017 at "Cell"
DOI: 10.1016/j.cell.2017.03.034
Abstract: Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing… read more here.
Keywords: parp inhibitors; parp; cancer; inhibitors cancer ... See more keywords
Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Medical hypotheses"
DOI: 10.1016/j.mehy.2020.109723
Abstract: The serine-threonine kinase CK2, which targets over 300 cellular proteins, is overexpressed in all cancers, presumably reflecting its ability to promote proliferation, spread, and survival through a wide range of complementary mechanisms. Via an activating… read more here.
Keywords: flavones flavonols; cancer; ck2 inhibitors; inhibitors cancer ... See more keywords
Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
Sign Up to like & getrecommendations! Published in 2019 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2019.114771
Abstract: Through synthesis of two rare phosphoinositides, PtdIns(3,5)P2 and PtdIns5P, the ubiquitously expressed phosphoinositide kinase PIKfyve is implicated in pleiotropic cellular functions. Small molecules specifically inhibiting PIKfyve activity cause cytoplasmic vacuolation in all dividing cells in… read more here.
Keywords: pikfyve; pikfyve inhibitors; cancer cells; cancer ... See more keywords
In Silico Discovery of JMJD6 Inhibitors for Cancer Treatment.
Sign Up to like & getrecommendations! Published in 2019 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.9b00264
Abstract: The 2-oxoglutarate (2OG)-dependent oxygenase JMJD6 is emerging as a potential anticancer target, but its inhibitors have not been reported so far. In this study, we reported an in silico protocol to discover JMJD6 inhibitors targeting… read more here.
Keywords: jmjd6; jmjd6 inhibitors; discovery jmjd6; silico discovery ... See more keywords
Advances in the discovery of exosome inhibitors in cancer
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Enzyme Inhibition and Medicinal Chemistry"
DOI: 10.1080/14756366.2020.1754814
Abstract: Abstract Exosomes are small membrane vesicles released by most eukaryotic cells. They are considered to play an essential role in cell-to-cell communication, and It is also found that they serve as functional mediators in many… read more here.
Keywords: discovery exosome; advances discovery; chemistry; exosome inhibitors ... See more keywords
Opinion: PARP inhibitors in cancer—what do we still need to know?
Sign Up to like & getrecommendations! Published in 2022 at "Open Biology"
DOI: 10.1098/rsob.220118
Abstract: PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi… read more here.
Keywords: opinion parp; parp; cancer still; still need ... See more keywords
Therapeutic YY1 Inhibitors in Cancer: ALL in ONE.
Sign Up to like & getrecommendations! Published in 2017 at "Critical reviews in oncogenesis"
DOI: 10.1615/critrevoncog.2017020472
Abstract: Various targeted therapies for cancer have resulted in a significant prolongation of survival and a better quality of life. However, unfortunately, a small subset of cancer patients responds to such therapies initially and then develops… read more here.
Keywords: yy1 inhibitors; cancer one; therapeutic yy1; cancer ... See more keywords
Histone Deacetylase Inhibitors in Cancer Therapy.
Sign Up to like & getrecommendations! Published in 2018 at "Current topics in medicinal chemistry"
DOI: 10.2174/1568026619666181210152115
Abstract: Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through… read more here.
Keywords: deacetylase inhibitors; histone deacetylase; cancer therapy; cancer ... See more keywords
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
Sign Up to like & getrecommendations! Published in 2022 at "Biomolecules"
DOI: 10.3390/biom12060815
Abstract: Ribonucleotide reductase (RR) is an essential multi-subunit enzyme found in all living organisms; it catalyzes the rate-limiting step in dNTP synthesis, namely, the conversion of ribonucleoside diphosphates to deoxyribonucleoside diphosphates. As expression levels of human… read more here.
Keywords: cancer target; inhibitors cancer; ribonucleotide reductase; reductase ... See more keywords
Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
Sign Up to like & getrecommendations! Published in 2017 at "Cancers"
DOI: 10.3390/cancers9110152
Abstract: mTOR inhibitors have demonstrated remarkable anti-tumor activity in experimental models, mainly by reducing cancer cell growth and tumor angiogenesis. Their use in cancer patients as monotherapy has, however, generated only limited benefits, increasing median overall… read more here.
Keywords: mtor inhibitors; future relevance; mtor; cancer ... See more keywords
Immune checkpoint inhibitors in cancer therapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Biomedical Research"
DOI: 10.7555/jbr.31.20160168
Abstract: In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types of immunotherapy on the horizon. There has been particular focus on the immune checkpoint molecules, cytotoxic T-lymphocyte antigen-4… read more here.
Keywords: immune checkpoint; checkpoint inhibitors; checkpoint; inhibitors cancer ... See more keywords